




**UNIVERSITI PUTRA MALAYSIA**

***IN VITRO* CYTOTOXICITY AND *IN VIVO* ANTITUMOUR PROPERTIES OF  
KENAF SEED OIL TOWARDS LEUKAEMIA**

**FOO JHI BIAU**

**IB 2011 12**

***IN VITRO* CYTOTOXICITY AND *IN VIVO* ANTITUMOUR PROPERTIES OF  
KENAF SEED OIL TOWARDS LEUKAEMIA**



**BY**

**FOO JHI BIAU**

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in  
Fulfilment of the Requirements for the Degree of Master of Science**

**November 2011**

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Master of Science

***IN VITRO* CYTOTOXICITY AND *IN VIVO* ANTITUMOUR PROPERTIES  
OF KENAF SEED OIL TOWARDS LEUKAEMIA**

By

**FOO JHI BIAU**

**November 2011**

**Chairman : Latifah Saiful Yazan, PhD**

**Faculty : Institute of Bioscience**

The current treatments for leukaemia such as chemotherapy and radiation therapy have prolonged the survival rate. However, the adverse effects of these treatments are difficult to handle. Thus, there is a need to seek for other remedies, such as the use of natural products. Natural products such as plants play an important role in the current cancer treatment. The advantage of using plant-derived anticancer agents is that the produced adverse effects are lesser as compared to the synthetic drugs. Kenaf (*Hibiscus cannabinus*) seed oil (KSO) is a rich source of bioactive phytochemicals with high anti-oxidative and cancer chemopreventive properties. Nevertheless, the anti-leukaemia properties of KSO have yet been investigated. This study investigated the anti-leukaemia properties of KSO *in vitro* and *in vivo*. KSO was extracted by

supercritical carbon dioxide fluid extractor (SFE), and evaluated for cytotoxic properties on leukaemia (HL-60, WEHI-3B and K562) and normal (3T3) cells by MTT assay with concentrations ranging from 50 to 800 µg/ml for 72 hours. The morphological changes of KSO-treated leukaemia cells were observed under an inverted light microscope and a fluorescence microscope. The cell cycle profile of KSO-treated leukaemia cells was analysed by flow cytometry. For *in vivo*, acute toxicity and anti-leukaemia properties of KSO were determined. Male BALB/c mice were injected intraperitoneally with WEHI-3B cells and administered orally with KSO at the dose of 0.5, 1.0 and 1.5 g/kg for 14 days. Upon completion, the blood of the mice was examined for the expression of cell surface marker of T cell (CD3), B cell (CD19), monocyte and granulocyte (CD11b) by staining with anti-CD3-FITC, anti-CD19-PE and anti-CD11b-PE antibodies, respectively. The livers and spleens were isolated, weighed and photographed. The spleens were processed for histopathological analysis. The yield of KSO by SFE ranged from 11 to 13% (w/w). KSO was found to be cytotoxic towards all the leukaemia cells in a dose-dependent manner with no effects on 3T3 cells even at the highest concentration employed (800 µg/ml). Oil from SFE at 600 bar 40 °C (KSO V600/40) was the most cytotoxic towards HL-60, WEHI-3B and K562 cells as compared to other extractions (KSO V600/60, KSO V600/80 and Soxhlet) with the 50% inhibition concentration (IC<sub>50</sub>) values of 178.78±10.52, 189.43±11.63 and 213.33±15.45 µg/ml, respectively. KSO V600/40-treated leukaemia cells exhibited typical characteristics of apoptosis such as cellular shrinkage, membrane blebbing, chromatin condensation and nuclear fragmentation. Cell cycle analysis revealed that KSO V600/40 at IC<sub>50</sub> value induced G1 phase cell cycle arrest and significantly increased (p<0.05) the sub-G1 apoptotic population in the leukaemia cells. For *in vivo*, acute toxicity study revealed that KSO

V600/40 did not cause any mortality in the healthy normal mice even at the highest dose (5.0 g/kg), suggesting that KSO is non-toxic by oral route. Treatment with KSO V600/40 at 1.0 and 1.5 g/kg increased the population of T cells, but decreased the population of immature monocytes and granulocytes in the blood of WEHI-3B injected BALB/c mice (WEHI-3B/BALB/c mice). Spleen and liver weight of WEHI-3B/BALB/c mice decreased after the treatment with KSO V600/40. Moreover, infiltration of leukaemic cells into the splenic red pulp reduced after the treatment, indicating that KSO V600/40 reduced the severity of leukaemia in WEHI-3B/BALB/c mice. In conclusion, KSO V600/40 showed cytotoxic effect via the induction of G1 phase cell cycle arrest and apoptosis in the leukaemia cells, and reduced the severity of leukaemia in WEHI-3B/BALB/c mice.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**PENGENALPASTIAN KESAN SITOTOKSIK *IN VITRO* DAN ANTITUMOR  
*IN VIVO* MINYAK BIJI KENAF TERHADAP LEUKEMIA**

Oleh

**FOO JHI BIAU**

**November 2011**

**Pengerusi : Latifah Saiful Yazan, PhD**

**Fakulti : Institut Biosains**

Rawatan untuk leukemia yang ada pada waktu ini seperti kemoterapi dan terapi radiasi telah meningkatkan tahap kehidupan. Walau bagaimanapun kesan sampingan daripada rawatan berkenaan adalah sukar ditangani. Oleh itu, adalah penting untuk mendapatkan kaedah rawatan yang lain seperti penggunaan bahan semulajadi. Bahan semulajadi seperti tumbuh-tumbuhan memainkan peranan yang penting dalam rawatan kanser pada masa kini. Kelebihan penggunaan agen antikanser berasaskan tumbuh-tumbuhan adalah dapat mengurangkan kesan sampingan berbanding ubatan sintetik. Minyak biji kenaf (*Hibiscus cannabinus*) (KSO) merupakan sumber yang kaya dengan fitokimia bioaktif dengan ciri anti-pengoksidaan yang tinggi dan pencegahan kanser. Namun demikian, ciri anti-leukemia KSO masih belum dikaji. Kajian ini dilakukan bagi menentukan kesan anti-leukemia KSO *in vitro* dan *in vivo*.

KSO diekstrak menggunakan pengestrak cecair karbon dioksida superkritikal (SFE) dan diuji kesan sitotoksik ke atas sel leukemia (HL-60, WEHI-3B dan K562) dan sel normal (3T3) pada kepekatan dalam julat 50 ke 800 µg/ml selama 72 jam. Perubahan morfologi sel leukemia yang dirawat dengan KSO diperhatikan di bawah mikroskop keterbalikan dan mikroskop pendarflour. Profil kitaran sel leukemia yang dirawat dengan KSO dianalisis dengan sitometri aliran. Bagi kajian *in vivo*, ciri ketoksikan akut dan anti-leukemia KSO ditentukan. Mencit BALB/c jantan disuntik dengan sel WEHI-3B secara intraperitoneal dan KSO diberi secara oral pada dos 0.5, 1.0 dan 1.5 g/kg selama 14 hari. Selepas tamat, darah mencit dikaji untuk kehadiran penanda permukaan sel T (CD3), sel B (CD19), monosit serta granulosit (CD11b) dengan pewarnaan dengan anti-CD3-FITC, anti-CD19-PE dan anti-CD11b-PE, masing-masing. Hati dan limpa mencit diasing, ditimbang dan diambil gambar. Limpa diproses untuk analisis histopatologi. Hasil pengestrakan KSO daripada SFE adalah di antara 11-13% (berat/berat). KSO didapati sitotoksik terhadap kesemua sel leukemia secara bersandar dos tanpa memberi kesan terhadap sel normal 3T3 walaupun pada kepekatan yang paling tinggi (800 µg/ml). Minyak yang terhasil daripada pengestrakan SFE pada 600 bar 40 °C (KSO V600/40) memberikan kesan sitotoksik yang paling tinggi terhadap sel HL-60, WEHI-3B dan K562 berbanding estrak yang lain (V600/60, V600/80 dan Soxhlet) dengan nilai  $IC_{50}$   $178.78 \pm 10.52$ ,  $189.43 \pm 11.63$  dan  $213.33 \pm 15.45$  µg/ml, masing-masing. Sel leukemia yang dirawat dengan KSO V600/40 menunjukkan ciri-ciri apoptosis seperti pengecutan sel, *blebbing*, kondensasi kromatin dan fragmentasi nukleus. Analisis kitaran sel menunjukkan KSO V600/40 pada nilai  $IC_{50}$  mengaruh penahanan kitaran sel pada fasa G1 dan meningkatkan populasi apoptosis sub-G1 secara signifikan ( $p < 0.05$ ) pada sel leukemia tersebut. Secara *in vivo*, kajian ketoksikan akut menunjukkan KSO

V600/40 tidak menyebabkan sebarang kematian pada normal mencit walaupun pada dos yang paling tinggi (5.0 g/kg). Ini menyaranakan bahawa KSO adalah tidak toksik apabila diberi secara oral. Rawatan dengan KSO V600/40 pada 1.0 and 1.5 g/kg meningkatkan populasi sel T, tetapi menurunkan populasi monosit dan granulosit yang tidak matang dalam darah mencit WEHI-3B/BALB/c. Berat limpa dan hati mencit WEHI-3B/BALB/c menurun selepas rawatan dengan KSO V600/40. Sebagai tambahan, infiltrasi sel leukemia ke dalam pulpa merah limpa menurun selepas rawatan, menunjukkan KSO V600/40 mengurangkan kesan teruk leukemia pada mencit WEHI-3B/BALB/c. Secara kesimpulannya, KSO V600/40 mengaruh penahanan kitaran sel pada fasa G1 dan apoptosis pada sel leukemia, dan mengurangkan keterukan leukemia pada mencit BALB/c yang diaruh WEHI-3B.



## ACKNOWLEDGEMENT

“Rome was not built in a day” – so goes the famous saying, and the completion of a project of any scale would most definitely not be accomplished with the efforts of one individual alone. Therefore, I would like to take this opportunity to express my deepest gratitude to several individuals, who lent their support in various ways throughout the duration of my study.

First and foremost, I would like to express my deepest gratitude to my supervisor, Dr. Latifah Saiful Yazan for her valuable guidance, suggestions, encouragement and believing in my research capabilities throughout my project and preparation of the thesis.

I would like to extend my sincere gratitude to my co-supervisor, Professor Maznah Ismail for her support and valuable discussion in making this research a success. Thank you for your kindness to help when I need it most.

Not to be forgotten to express my sincere thanks to Associate Professor Dr. Johnson Stanlas, Associate Professor Dr. Siddig Ibrahim Abdelwahab, Dr. Syam Mohan and Dr. Teo Guan Young for your generosity to help throughout the study. The ideas and guidance are appreciated.

I am very grateful to all science officers, assistants and technicians in Institute of Bioscience, Universiti Putra Malaysia, Mrs. Siti Muskinah, Ms. Norsha, Mr. Kim Wei, Mr. Abidin, Mrs. Mastura, Ms. Siti Aisyah, Mrs. Lina, Mrs. Nancy, Mrs.

Norhafiza, Ms. Normahfuzah, Dr. Tan Sheau Wei and Mrs. Tommini; Staff of Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Mrs. Amrina, Mrs. Normah, Mrs. Juita, and Mrs. Zamzarina. Thank you very much for your guidance, kind assistance, informative description about the equipment, chemicals in the laboratory as well as the methods of handling and operating them.

Special thanks go to my group members and friends Mr. Hisyam, Mrs. Noreen, Mr. Zulfahmi, Mrs. Norsyafini, Mrs. Aina, Ms. Armania, Mr. Wei Keat, Mr. Chee Wun, Ms. Sandy Mun Waei, Ms. Aisyah, Mr. Yusri, Ms. Su Hua and Ms. Huan Yong who have helped me directly and indirectly for the past three years. Thank you for willing to share with me your knowledge. Learning from you all is one of the most beautiful things happened in my life.

I would also like to acknowledge the financial support from Ministry of Plantation Industries and Commodities Malaysia (research grant) and the Universiti Putra Malaysia (Graduate Research Fellowship) for my study.

Last but not least, my deepest appreciation to my parents who have made me who I am today and my siblings who have always been there for me.

I certify that a Thesis Examination Committee has met on 24 November 2011 to conduct the final examination of Foo Jhi Biau on his thesis entitled “*In vitro* Cytotoxicity and *In Vivo* Antitumour Properties of Kenaf Seed Oil Towards Leukaemia” in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Master of Science.

Members of the Thesis Examination Committee were as follows:

**Huzwah binti Khazaai, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Norhaizan binti Mohd Esa, PhD**

Associate Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Internal Examiner)

**Sharida binti Fakurazi, PhD**

Associate Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Internal Examiner)

**Nor Fadilah Rajab, PhD**

Associate Professor  
Faculty of Health Sciences  
Universiti Kebangsaan Malaysia  
(External Examiner)



---

**SEOW HENG FONG, PhD**

Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date: 25 January 2012

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of **Master of Science**. The members of the Supervisory Committee were as follows:

**Latifah Saiful Yazan, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Maznah Ismail, PhD**

Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)



---

**BUJANG BIN KIM HUAT, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

## DECLARATION

I declare that the thesis is my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.



---

**FOO JHI BIAU**

Date: 24 November 2011

## TABLE OF CONTENTS

|  | <b>Page</b> |
|--|-------------|
| <b>ABSTRACT</b>  | iii         |
| <b>ABSTRAK</b>   | vi          |
| <b>ACKNOWLEDGEMENTS</b>  | ix          |
| <b>APPROVAL</b>  | xi          |
| <b>DECLARATION</b>   | xiii        |
| <br>   |             |
| <b>CHAPTER</b>   |             |
| <br>   |             |
| <b>1 INTRODUCTION</b>  | <b>1</b>    |
| <br>   |             |
| <b>2 LITERATURE REVIEW</b>   | <b>5</b>    |
| 2.1 Leukaemia  | 5           |
| 2.1.1 Acute myeloid leukaemia  | 6           |
| 2.1.2 Acute lymphocytic leukaemia  | 8           |
| 2.1.3 Chronic myeloid leukaemia  | 9           |
| 2.1.4 Chronic lymphocytic leukaemia  | 10          |
| 2.2 Leukaemic cell line  | 11          |
| 2.2.1 Human promyelocytic leukaemic cells                                  | 11          |
| 2.2.2 Murine myelomonocytic leukaemic cells                                | 12          |
| 2.2.3 Human chronic myelogenous leukaemic cells                            | 14          |
| 2.3 Supercritical carbon dioxide fluid extraction                          | 15          |
| 2.4 <i>Hibiscus cannabinus</i> (Kenaf)                                     | 18          |
| 2.4.1 Yield of kenaf seed oil  | 20          |
| 2.4.2 Chemical composition of kenaf seed oil                               | 21          |
| 2.5 Apoptosis  | 25          |
| 2.6 Cell cycle   | 29          |
| <br>   |             |
| <b>3 MATERIALS AND METHODS</b>   | <b>32</b>   |
| 3.1 Experimental design  | 32          |
| 3.2 Materials and equipment  | 33          |
| 3.2.1 Kenaf seeds  | 33          |
| 3.2.2 Cell culture   | 33          |
| 3.2.3 Cytotoxicity study   | 34          |
| 3.2.4 Morphological study  | 34          |
| 3.2.5 Cell cycle analysis  | 34          |
| 3.2.6 Animal and induction of leukaemia                                    | 34          |
| 3.2.7 Determination of the expression of white blood cells surface markers | 35          |
| 3.2.8 Haematoxylin and eosin staining                                      | 35          |
| 3.3 Methods  | 36          |
| 3.3.1 Kenaf seed oil extraction  | 36          |
| 3.3.2 <i>In vitro</i> study  | 37          |
| 3.3.3 <i>In vivo</i> study   | 41          |
| 3.4 Statistical analysis   | 47          |

|   |   |     |
|---|---|-----|
| 4 | <b>KENAF SEED OIL FROM SUPERCRITICAL CARBON DIOXIDE FLUID EXTRACTION INDUCED G1 PHASE CELL CYCLE ARREST AND APOPTOSIS IN LEUKAEMIA CELLS</b>  | 48  |
|   | Copyright permission/Acceptance letter  | 69  |
| 5 | <b>KENAF SEED OIL FROM SUPERCRITICAL CARBON DIOXIDE FLUID EXTRACTION INHIBITS THE PROLIFERATION OF WEHI-3B LEUKAEMIA CELLS <i>IN VIVO</i></b> | 71  |
|   | Copyright permission/Acceptance letter  | 92  |
| 6 | <b>GENERAL DISCUSSION</b>   | 93  |
| 7 | <b>SUMMARY, GENERAL CONCLUSION AND RECOMMENDATION FOR FUTURE RESEARCH</b>   | 97  |
|   | 6.1 Summary and general conclusion  | 97  |
|   | 6.2 Recommendation  | 99  |
|   | <b>REFERENCES</b>   | 100 |
|   | <b>APPENDICES</b>   | 113 |
|   | <b>BIODATA OF STUDENT</b>   | 116 |